TL;DR
This paper explores the potential of novel biodegradable copolymers, poly(L-lactide-co-trimethylene carbonate) (PLT), for use as cardiac occluders. The study demonstrates that these copolymers exhibit excellent biocompatibility and controlled degradation rates, making them promising candidates to replace permanent metallic occluders and mitigate associated complications.
What Problem Does This Paper Address?
Congenital heart diseases are often treated with cardiac occluders, with Amplatzer occluders being the current standard. While effective in the short term, these devices are made of permanent metallic materials that can lead to serious long-term complications like hemolysis, thrombosis, and allergic reactions. This necessitates the development of degradable occluders that can perform their function and then safely resorb into the body, eliminating the risk of chronic issues. Previous attempts at degradable occluders have faced challenges in balancing mechanical strength, elasticity, and degradation timing. This paper aims to address this by investigating PLLA-TMC copolymers, which offer a tunable balance of properties for this specific application.
Methods
The researchers synthesized a series of PLLA-TMC copolymers with varying ratios of L-lactide (LLA) and trimethylene carbonate (TMC) using ring-opening polymerization. They characterized these copolymers using standard techniques:
- ¹H NMR and ¹³C NMR: To determine the chemical composition and block lengths.
- GPC (Gel Permeation Chromatography): To measure molecular weight and dispersity.
- DSC (Differential Scanning Calorimetry): To assess thermal properties like glass transition temperature (Tg).
- Tensile Testing: To evaluate mechanical properties such as tensile strength and elongation at break.
For evaluating their suitability as cardiac occluders, the study employed:
- In vitro degradation: Samples were incubated in phosphate-buffered saline (PBS) at 37°C to monitor mass loss, water uptake, and molar mass changes over time.
- Hemocompatibility tests: Including hemolysis, dynamic clotting time, and plasma recalcification time to assess interactions with blood components.
- Cytotoxicity tests (MTT assay): To evaluate the effect of copolymer extracts on L-929 mouse fibroblast cells.
- In vivo degradation and histocompatibility: 3D printed occluder prototypes made from the best-performing copolymer (PLT 70/30) were implanted into rabbits to observe degradation, tissue response, and inflammatory reactions through histological examination (H&E staining).
Datasets
Not discussed in the paper.
Key Insights and Ideas
- Tunable Properties: The LLA/TMC ratio is a critical factor in controlling the copolymer's properties. Increasing TMC content leads to a lower glass transition temperature (Tg), increased flexibility (higher elongation at break), and slower degradation rates.
- Amorphous Nature is Beneficial: The synthesized copolymers are amorphous, which is advantageous for biomedical applications as high crystallinity in biomaterials can sometimes lead to late inflammatory reactions.
- Degradation Kinetics: In vitro degradation showed that higher TMC content correlates with slower degradation, while in vivo studies revealed a degradation period of approximately 120 days for the selected PLT 70/30 copolymer, which aligns with the required functional support time for cardiac occluders (1-3 months).
- Controlled Degradation Products: The degradation of PLLA units was observed to be faster than TMC units, and interestingly, crystallization of PLLA-rich degradation by-products was noted at later stages of in vivo degradation, potentially influencing the degradation profile and resistance.
- Excellent Biocompatibility: The PLT copolymers demonstrated very low cytotoxicity and good hemocompatibility, with minimal impact on red blood cells and coagulation parameters, suggesting they are safe for blood contact.
- Successful In Vivo Performance: 3D printed PLT 70/30 occluders showed good tissue integration and gradual degradation in rabbits, with minimal inflammatory response, confirming their potential for in vivo application.
Key Results
- Mechanical Properties: Tensile strength decreased from 31.5 MPa (PLT 75/25) to 16.5 MPa (PLT 60/40), while elongation at break increased from 87% to 512% with increasing TMC content.
- In Vitro Degradation: Mass loss after 90 days was around 4.7-6.5%, with water uptake varying from 9-15%. Molar mass decreased significantly, with PLT 75/25 showing the fastest decrease.
- Hemocompatibility: Hemolysis ratios were consistently below 5% for all copolymers. Dynamic clotting times were shorter than the negative control but longer than the positive control, indicating minimal pro-coagulant effect. Plasma recalcification times were significantly longer than the positive control, suggesting no adverse effect on the intrinsic coagulation pathway.
- Cytotoxicity: Relative growth rate (RGR) values for all copolymer extracts were above 100%, indicating no cytotoxic effects and a cytotoxicity level of 0.
- In Vivo Degradation: PLT 70/30 occluders degraded over 120 days, with initial flattening observed due to Tg being close to body temperature, followed by gradual deformation and near-complete degradation. Histological examination showed good tissue compatibility with minimal inflammation.
Limitations and Future Work
The authors acknowledge that the 3D printing process at high temperatures led to a significant decrease in molar mass, suggesting that printing conditions need to be carefully controlled to minimize thermal degradation. They also note that the Tg of the PLT 60/40 copolymer was below body temperature, which might affect its structural integrity in vivo.
Future work will focus on optimizing copolymer properties, occluder architecture, and the matching of occluders with guidewires for potential clinical applications. Further studies are underway to fine-tune these aspects for successful clinical translation.
Summary updated